A Phase I trial (NCT03875820) explored the combination of VS-6063 (a FAK inhibitor) and RO5126766 (a RAF/MEK inhibitor) in patients with advanced RAS-mutant solid tumors, including non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). Here, MAP2K7 is linked to non-small cell lung carcinoma.